Cell-free production enables bypassing bacterial fermentation, making high-purity DNA accessible in just 2-4 weeks without plasmid backbones or other unnecessary DNA elements.
Fully Synthetic DNA For Cleaner, More Controlled Starting Material
Synthetic oDNA is a double-stranded linear DNA molecule composed of the therapeutic coding sequence, an application-specific DNA architecture, and proprietary non-coding adaptor sequences that optimize performance while preserving the therapeutic sequence.
Allows for starting material flexibility, efficient amplification, and optimized DNA performance.
Every advanced therapy is different, with unique requirements for performance, delivery, and manufacturability. To enable application-specific oDNA constructs without modifying the therapeutic sequence, oDNA is designed to be optimized through TWO KEY FEATURES:
Different applications benefit from different DNA molecule structures.
oDNA can be engineered in multiple molecular formats with open or closed ends. Each end can be independently designed to optimize manufacturability and downstream performance for specific applications, allowing for symmetric or asymmetric formats, depending on goals.
Application-based adaptor modules tailor GOI function to end goals.
Adaptor sequences are programmable, non-coding DNA elements that surround the therapeutic coding sequence. They are engineered to optimize construct performance for each application while leaving the therapeutic sequence unchanged.
LINEAR CLOSED
Ideal for viral & non-viral gene therapy, DNA-based vaccines & therapies, and gene editing applications.
LINEAR PARTIALLY CLOSED
This molecular format is optimal for RNA-based vaccines and RNA-based therapies.
LINEAR OPEN
This molecular format is optimal for RNA-based vaccines and RNA-based therapies.
DNA persistence within cells can be improved using non-natural nucleotides.
Transcription is supported by sequence or structure-guided adaptors inspired by RNA polymerase crystal structures, optimizing promoter recognition and improving IVT efficiency.
Targeting may be achieved through adaptors functionalized with ligands that bind specific cell-surface receptors, enabling selective uptake in desired cell populations.
Higher expression at DNA level can be achieved by improving multiple upstream and downstream steps that determine functional payload availability.
Translocation can be facilitated by adaptors incorporating nuclear localization signals (NLS), or aptamers that promote nuclear import.
Release can be improved using adaptors that promote endosomal escape, among others.
Immunogenic Responses can be modulated through the use of modified nucleotides.
Structure-guided oDNA adapters, designed based on T7 RNA polymerase crystal structure, improve T7 polymerase kinetics, leading to higher transcription rate and efficiency (↓Km, ↑Vmax) and increased RNA yield.
Stem Cells 
CAR-T 
AAV Delivery 
LVV Delivery 
Other Viral Vectors 
Extracellular Vesicles 
Nanoparticles